Literature DB >> 14531904

Possible regulation of Wilms' tumour gene 1 (WT1) expression by the paired box genes PAX2 and PAX8 and by the haematopoietic transcription factor GATA-1 in human acute myeloid leukaemias.

Jan M Siehl1, Eckhard Thiel, Karin Heufelder, Emilian Snarski, Stefan Schwartz, Volker Mailänder, Ulrich Keilholz.   

Abstract

Overexpression of the embryonic transcription factor, Wilms' tumour protein 1 (WT1), is common in acute myeloid leukaemias (AML). Mutations of Wilms' tumour gene 1 (WT1) in AML are rare and WT1 expression may be increased by other transcription factors. PAX2, PAX8 and GATA-1 are known physiological regulators of WT1. In the present study, we analysed either bone marrow or blood samples of 43 AML patients for the expression levels of WT1, PAX2, PAX8 and GATA-1 by real-time reverse transcription polymerase chain reaction (LightCycler). Bone marrow samples of patients without haematological malignancies and stem cell preparation samples from healthy donors and lymphoma patients served as controls. PAX2 expression was found in 11 of 43 AML samples, with a clear correlation of PAX2 with WT1 expression levels observed. PAX8 expression was found in two additional samples. GATA-1 expression was detectable in 41 of 43 AML samples and also in all control samples; no significant differences between these groups were observed and no correlation of GATA-1 expression with WT1 expression levels was apparent. In conclusion, PAX2, and possibly PAX8, appears to be a candidate for the upregulation of WT1 in a proportion of AML, whereas GATA-1 expression cannot be explained as an inducer of WT1. In two-thirds of leukaemias from our series, the basis of WT1 upregulation cannot be explained by the simple upregulation of the known WT1 activators.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14531904     DOI: 10.1046/j.1365-2141.2003.04622.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  TGF-beta1 reduces Wilms' tumor suppressor gene expression in podocytes.

Authors:  Toru Sakairi; Yoshifusa Abe; Jeffrey B Kopp
Journal:  Nephrol Dial Transplant       Date:  2011-03-04       Impact factor: 5.992

2.  Cytoplasmic Localization of WT1 and Decrease of miRNA-16-1 in Nephrotic Syndrome.

Authors:  Pablo Zapata-Benavides; Mariela Arellano-Rodríguez; Juan José Bollain-Y-Goytia; Moisés Armides Franco-Molina; Gloria Azucena Rangel-Ochoa; Esperanza Avalos-Díaz; Rafael Herrera-Esparza; Cristina Rodríguez-Padilla
Journal:  Biomed Res Int       Date:  2017-02-19       Impact factor: 3.411

3.  LncRNA-PAX8-AS1 Silencing Decreases Cell Viability, Enhances Apoptosis, and Suppresses Doxorubicin Resistance in Myeloid Leukemia via the miR-378g/ERBB2 Axis.

Authors:  Xiaolu Song; Yirui Chen; Ye Peng; Xiaogang Wang; Sujie Zheng; Fangfang Shi; Jianping Lan
Journal:  Evid Based Complement Alternat Med       Date:  2022-10-06       Impact factor: 2.650

4.  Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination.

Authors:  Antonia Busse; Anne Letsch; Carmen Scheibenbogen; Anika Nonnenmacher; Sebastian Ochsenreither; Eckhard Thiel; Ulrich Keilholz
Journal:  J Transl Med       Date:  2010-01-21       Impact factor: 5.531

5.  PAX8 is a novel marker for differentiating between various types of tumor, particularly ovarian epithelial carcinomas.

Authors:  Li Xiang; Beihua Kong
Journal:  Oncol Lett       Date:  2013-01-10       Impact factor: 2.967

6.  An intron 9 containing splice variant of PAX2.

Authors:  Antonia Busse; Anika Rietz; Stefan Schwartz; Eckhard Thiel; Ulrich Keilholz
Journal:  J Transl Med       Date:  2009-05-25       Impact factor: 5.531

7.  The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells.

Authors:  Youqi Han; Serban San-Marina; Lin Yang; Haytham Khoury; Mark D Minden
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

8.  Expression and prognosis analysis of TET family in acute myeloid leukemia.

Authors:  Tingjuan Zhang; Yangli Zhao; Yangjing Zhao; Jingdong Zhou
Journal:  Aging (Albany NY)       Date:  2020-03-25       Impact factor: 5.682

9.  EZH2 dysregulation: Potential biomarkers predicting prognosis and guiding treatment choice in acute myeloid leukaemia.

Authors:  Ming-Qiang Chu; Ting-Juan Zhang; Zi-Jun Xu; Yu Gu; Ji-Chun Ma; Wei Zhang; Xiang-Mei Wen; Jiang Lin; Jun Qian; Jing-Dong Zhou
Journal:  J Cell Mol Med       Date:  2019-12-03       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.